Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma-Reference-Cited by-同舟云学术

Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma

Published:2007-08-01 Issue:8 Volume:12 Page:978-990
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Manochakian Rami¹,Miller Kena C.¹,Chanan-Khan Asher A.¹

Affiliation:

1. Roswell Park Cancer Institute, Buffalo, New York, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Discuss the efficacy of bortezomib as part of primary therapy for patients with multiple myeloma.Describe the safety of bortezomib and bortezomib-based regimens in patients with previously untreated multiple myeloma.Identify new management options for patients with treatment-naïve multiple myeloma. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-8-978

Reference98 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. Cancer incidence and mortality in Europe, 2004;Boyle;Ann Oncol,2005

3. Multiple myeloma;Sirohi;Lancet,2004

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of the Mechanistic Target of Rapamycin Can Ameliorate Bortezomib-Induced Peripheral Neuropathy;Biological and Pharmaceutical Bulletin;2023-08-01

2. Discovery and clinical introduction of first-in-class imipridone ONC201;Oncotarget;2016-09-01

3. Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy;PLOS ONE;2015-04-14

4. Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma;Redox Biology;2015-04

5. Recovery of kidney function following delayed use of theralite dialyzer in a patient with myeloma cast nephropathy;Clinical Nephrology;2013-04-01